tradingkey.logo

MaxCyte Inc

MXCT
0.808USD
0.0000.00%
Fechamento 02/06, 16:00ETCotações atrasadas em 15 min
86.17MValor de mercado
PerdaP/L TTM

Mais detalhes de MaxCyte Inc Empresa

MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.

Informações de MaxCyte Inc

Código da empresaMXCT
Nome da EmpresaMaxCyte Inc
Data de listagemMar 29, 2016
CEOMasoud (Maher)
Número de funcionários114
Tipo de títulosOrdinary Share
Fim do ano fiscalMar 29
Endereço9713 Key West Avenue,
CidadeROCKVILLE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal20850
Telefone13015175556
Sitehttps://www.maxcyte.com/
Código da empresaMXCT
Data de listagemMar 29, 2016
CEOMasoud (Maher)

Executivos da empresa MaxCyte Inc

Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Stanley C. (Stan) Erck
Mr. Stanley C. (Stan) Erck
Non-Executive Independent Director
Non-Executive Independent Director
398.33K
+100000.00%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
230.58K
+80000.00%
Mr. Maher Masoud, J.D.
Mr. Maher Masoud, J.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
175.00K
+75000.00%
Mr. John Joseph Johnston
Mr. John Joseph Johnston
Non-Executive Independent Director
Non-Executive Independent Director
171.16K
+29210.00%
Dr. Yasir B. Al-Wakeel
Dr. Yasir B. Al-Wakeel
Non-Executive Independent Director
Non-Executive Independent Director
50.58K
+29210.00%
Mr. Douglas J. (Doug) Swirsky
Mr. Douglas J. (Doug) Swirsky
Chief Financial Officer
Chief Financial Officer
50.00K
+50000.00%
Ms. Rekha Hemrajani
Ms. Rekha Hemrajani
Non-Executive Independent Director
Non-Executive Independent Director
39.89K
+18526.00%
Mr. William W. (Will) Brooke, J.D.
Mr. William W. (Will) Brooke, J.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Patrick J. Balthrop
Mr. Patrick J. Balthrop
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. David Sandoval
Mr. David Sandoval
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Stanley C. (Stan) Erck
Mr. Stanley C. (Stan) Erck
Non-Executive Independent Director
Non-Executive Independent Director
398.33K
+100000.00%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
230.58K
+80000.00%
Mr. Maher Masoud, J.D.
Mr. Maher Masoud, J.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
175.00K
+75000.00%
Mr. John Joseph Johnston
Mr. John Joseph Johnston
Non-Executive Independent Director
Non-Executive Independent Director
171.16K
+29210.00%
Dr. Yasir B. Al-Wakeel
Dr. Yasir B. Al-Wakeel
Non-Executive Independent Director
Non-Executive Independent Director
50.58K
+29210.00%
Mr. Douglas J. (Doug) Swirsky
Mr. Douglas J. (Doug) Swirsky
Chief Financial Officer
Chief Financial Officer
50.00K
+50000.00%

Detalhamento da receita

Moeda: USDAtualizado em: ter, 6 de jan
Moeda: USDAtualizado em: ter, 6 de jan
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
Por EmpresaUSD
Nome
Receita
Proporção
Product sales
3.95M
57.89%
Product
3.95M
57.89%
Licenses
2.23M
32.60%
other
650.00K
9.52%
Por RegiãoUSD
Nome
Receita
Proporção
Inside the United States
3.84M
56.17%
Outside the United States
2.99M
43.83%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Product sales
3.95M
57.89%
Product
3.95M
57.89%
Licenses
2.23M
32.60%
other
650.00K
9.52%

Distribuição de ações

Atualizado em: sáb, 7 de fev
Atualizado em: sáb, 7 de fev
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Cadian Capital Management LP
7.71%
Capricorn Fund Managers Ltd
7.69%
Mirabella Financial Services LLP
7.69%
BlackRock Institutional Trust Company, N.A.
7.54%
The Vanguard Group, Inc.
5.19%
Outro
64.18%
Investidores
Investidores
Proporção
Cadian Capital Management LP
7.71%
Capricorn Fund Managers Ltd
7.69%
Mirabella Financial Services LLP
7.69%
BlackRock Institutional Trust Company, N.A.
7.54%
The Vanguard Group, Inc.
5.19%
Outro
64.18%
Tipos de investidores
Investidores
Proporção
Investment Advisor
29.83%
Investment Advisor/Hedge Fund
24.34%
Hedge Fund
17.87%
Research Firm
4.86%
Private Equity
4.73%
Individual Investor
1.74%
Venture Capital
0.36%
Bank and Trust
0.19%
Pension Fund
0.15%
Outro
15.93%

Participação acionária institucional

Atualizado em: qui, 1 de jan
Atualizado em: qui, 1 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
282
79.67M
74.69%
-13.89M
2025Q3
287
82.96M
77.85%
-17.02M
2025Q2
296
78.80M
73.92%
-18.62M
2025Q1
308
82.56M
77.59%
-14.89M
2024Q4
308
80.42M
75.91%
-14.30M
2024Q3
300
80.65M
76.72%
-18.62M
2024Q2
297
80.25M
76.66%
-17.97M
2024Q1
302
79.09M
75.86%
-22.52M
2023Q4
303
79.97M
77.01%
-14.24M
2023Q3
292
77.05M
74.47%
-17.27M
Ver Mais

Atividade dos acionistas

Nome
Ações detidas
Proporção
Variação
Var. %
Data
Cadian Capital Management LP
8.23M
7.71%
-686.87K
-7.71%
Sep 30, 2025
Mirabella Financial Services LLP
8.20M
7.69%
+1.60M
+24.24%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
8.04M
7.54%
-168.77K
-2.06%
Sep 30, 2025
The Vanguard Group, Inc.
5.59M
5.24%
-13.59K
-0.24%
Sep 30, 2025
River Global Investors LLP
5.50M
5.15%
+2.24M
+68.99%
Oct 23, 2025
Vitruvian Partners LLP
5.04M
4.73%
--
--
Sep 30, 2025
Morgan Stanley & Co. LLC
4.25M
3.98%
+12.10K
+0.29%
Sep 30, 2025
Mudita Advisors LLP
3.37M
3.16%
--
--
Sep 30, 2025
AXA Investment Managers UK Ltd.
2.77M
2.6%
+571.18K
+25.93%
Sep 30, 2025
Ver Mais

ETFs Relacionados

Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
Invesco NASDAQ Future Gen 200 ETF
0.6%
iShares Micro-Cap ETF
0.03%
Invesco Nasdaq Biotechnology ETF
0.02%
Avantis US Small Cap Equity ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.02%
iShares Russell 2000 Value ETF
0.01%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 ETF
0.01%
Global X Russell 2000 ETF
0.01%
iShares Biotechnology ETF
0.01%
Ver Mais
Invesco NASDAQ Future Gen 200 ETF
Proporção0.6%
iShares Micro-Cap ETF
Proporção0.03%
Invesco Nasdaq Biotechnology ETF
Proporção0.02%
Avantis US Small Cap Equity ETF
Proporção0.02%
ProShares Ultra Nasdaq Biotechnology
Proporção0.02%
iShares Russell 2000 Value ETF
Proporção0.01%
Proshares Ultra Russell 2000
Proporção0.01%
iShares Russell 2000 ETF
Proporção0.01%
Global X Russell 2000 ETF
Proporção0.01%
iShares Biotechnology ETF
Proporção0.01%

Dividendo

Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados

Desdobramento de ações

Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
KeyAI